Detalhe da pesquisa
1.
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.
EMBO Rep
; 24(8): e55884, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366231
2.
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
BMC Cancer
; 22(1): 732, 2022 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35790916
3.
Hyperprogressive Disease: Main Features and Key Controversies.
Int J Mol Sci
; 22(7)2021 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33916696
4.
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Int J Mol Sci
; 20(7)2019 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30986912
5.
CAR-T Cells for the Treatment of Lung Cancer.
Life (Basel)
; 12(4)2022 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35455052
6.
Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer.
Cancers (Basel)
; 14(16)2022 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36010840
7.
Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma.
Cancers (Basel)
; 13(2)2021 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33478100
8.
Effects of a Multicomponent Exercise Program in Older Adults with Non-Small-Cell Lung Cancer during Adjuvant/Palliative Treatment: An Intervention Study.
J Clin Med
; 9(3)2020 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32245169
9.
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.
Cancers (Basel)
; 12(2)2020 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32033028
10.
Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells.
J Clin Med
; 9(2)2020 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32012729
11.
Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer.
Cancers (Basel)
; 11(7)2019 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31284372
12.
Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
BMC Pharmacol Toxicol
; 20(1): 68, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753013
13.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
; 9: 707, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31448227
14.
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Front Oncol
; 9: 967, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31598491
15.
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
EMBO Mol Med
; 11(7): e10293, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31273938
16.
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.
J Clin Med
; 8(12)2019 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31835708
17.
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.
Front Oncol
; 9: 193, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30984619
18.
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.
Aging (Albany NY)
; 11(9): 2874-2888, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31076561
19.
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors.
Transl Lung Cancer Res
; 12(6): 1332-1334, 2023 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37425415
20.
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.
Oncotarget
; 9(86): 35687-35704, 2018 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30479698